A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting

被引：0
|
作者：
Laura McCullagh
Lesley Tilson
Cathal Walsh
Michael Barry
机构：
[1] St James’s Hospital,National Centre for Pharmacoeconomics
[2] Trinity College Dublin,Department of Statistics
来源：
PharmacoEconomics | 2009年 / 27卷
关键词：
Deep Venous Thrombosis; Dabigatran; Rivaroxaban; Total Knee Replacement; Probabilistic Sensitivity Analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: It has been estimated that major orthopaedic surgery has the highest risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) when compared with other surgery. Two new orally active anticoagulants have recently become licensed in Ireland for the primary prevention of venous thromboembolism in adult patients undergoing elective total hip replacement (THR) or total knee replacement (TKR). Rivaroxaban (Xarelto®) is a direct factor Xa inhibitor and dabigatran etexilate (Pradaxa®) is a prodrug of the active compound dabigatran, which inhibits thrombin.
引用
收藏
页码：829 / 846
页数：17
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN ETEXILATE VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
    Fernandes, R. A.
    Quintella, F. F.
    Teich, V. D.
    VALUE IN HEALTH, 2009, 12 (07) : A502 - A503
  • [22] COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY
    Weitz, J.
    Bernard, L.
    Wakeford, C.
    VALUE IN HEALTH, 2009, 12 (07) : A333 - A333
  • [23] Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement
    Freyburger, Genevieve
    Macouillard, Gerard
    Labrouche, Sylvie
    Sztark, Francois
    THROMBOSIS RESEARCH, 2011, 127 (05) : 457 - 465
  • [24] Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism in patients undergoing total hip replacement surgery
    Bradley-Kennedy, C.
    Wolowacz, S. E.
    Roskell, N. S.
    Plumb, J. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 786 - 786
  • [25] COST EFFECTIVENESS OF RIVAROXABAN AND DABIGATRAN ETEXILATE FOR THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AND ASSOCIATED LONG TERM COMPLICATIONS POST TOTAL HIP REPLACEMENT IN IRELAND
    McCullagh, L.
    Tilson, L.
    Walsh, C.
    Barry, M.
    VALUE IN HEALTH, 2009, 12 (07) : A334 - A334
  • [26] Cost-effectiveness of rivaroxaban for prevention of venous thromboembolism (VTE) after total hip or knee replacement (THR, TKR) in the USA
    Kwong, L.
    Duran, A.
    Diamantopoulos, A.
    Sengupta, N.
    Lees, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 787 - 787
  • [27] Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain
    Gomez-Outes, Antonio
    Avendano-Sola, Cristina
    Isabel Terleira-Fernandez, Ana
    Vargas-Castrillon, Emilio
    PHARMACOECONOMICS, 2014, 32 (09) : 919 - 936
  • [28] Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain
    Antonio Gómez-Outes
    Cristina Avendaño-Solá
    Ana Isabel Terleira-Fernández
    Emilio Vargas-Castrillón
    PharmacoEconomics, 2014, 32 : 919 - 936
  • [29] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT IN SLOVAKIA
    Lukac, M.
    Bielik, J.
    Lees, M.
    Foltan, V
    Tomek, D.
    VALUE IN HEALTH, 2010, 13 (07) : A520 - A520
  • [30] COST-EFFECTIVENESS OF APIXABAN AND ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT IN CHINA
    Yan, X. Y.
    Gu, X. H.
    Bu, J.
    Lin, H. W.
    Wu, B.
    VALUE IN HEALTH, 2016, 19 (07) : A651 - A651
12345